On August 11, 2026, the Board of Directors approved an increase in ordinary shares reserved for issuance under the Company’s 2024 Employee Equity Incentive Plan by 2,500,000 shares. The total number of shares reserved increased from 112,667 to 2,612,667. This filing is incorporated by reference into existing Form F-3 and Form S-8 registration statements. IceCure Medical Ltd. operates in the medical device industry, developing cryoablation technology for cancer treatment.
